aTYR Pharma Inc. (ATYR) intrinsic value & 10-year financials
aTYR Pharma Inc. (ATYR) has a Graham intrinsic value of $11.32 per share. At $0.17 on Oct 17, 2026, the stock trades 98% below that value. Over the last 10 fiscal years revenue shrank 12.4% a year to $190.0K, with an average return on invested capital of -89.7%.
- Graham intrinsic value
- $11.32
- Share price (Oct 17, 2026)
- $0.17
- Price vs Graham value
- 98% below
- Market cap
- $16.2M
- Revenue (FY2025)
- $190.0K
- Revenue growth (10-yr CAGR)
- -12.4%
- ROIC (10-yr avg)
- -89.7%
- Free cash flow (FY2025)
- -$62.1M
ATYR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $190.0K | -$74.1M | -$0.80 | -$62.1M | -40856.3% | -112.3% |
| FY2024 | $235.0K | -$64.0M | -$0.86 | -$69.2M | -28899.6% | -88.8% |
| FY2023 | $353.0K | -$50.4M | -$0.94 | -$37.4M | -15557.8% | -71.3% |
| FY2022 | $10.4M | -$45.3M | -$1.60 | -$43.5M | -446.8% | -51.7% |
| FY2021 | $0 | -$33.8M | -$1.77 | -$33.3M | — | -55.1% |
| FY2020 | $10.5M | -$16.2M | -$0.89 | -$15.5M | -152.2% | -81.5% |
| FY2019 | $422.0K | -$23.6M | — | -$20.1M | -5445.0% | -92.5% |
| FY2018 | — | -$34.5M | — | -$31.7M | — | -73.3% |
| FY2017 | — | -$48.2M | — | -$43.7M | — | -99.6% |
| FY2016 | — | -$57.9M | — | -$53.5M | — | -170.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
aTYR PHARMA INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
aTYR PHARMA INC has historically struggled to out-earn its cost of capital, averaging just -72.8% ROIC.
Over the decade, aTYR PHARMA INC shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, aTYR PHARMA INC is modeled at -12.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $11.32 per share.